These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 33942348)

  • 1. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.
    Wang H; Zhang Y; Li Z; Bai O
    Front Immunol; 2024; 15():1466859. PubMed ID: 39376572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
    Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.
    Bommier C; Donzel M; Rossi C; Fornecker LM; Bijou F; Chauchet A; Lebras L; Ysabaert L; Haioun C; Bouabdallah K; Gastinne T; Morineau N; Amorim S; Jardin F; Abraham J; Lamy de la Chapelle T; Gressin R; Fouillet L; Fruchart C; Olivier G; Morschhauser F; Cherblanc F; Belot A; Le Guyader S; Monnereau A; Ghesquieres H; Thieblemont C
    Hematol Oncol; 2024 Nov; 42(6):e3314. PubMed ID: 39351974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
    Vannata B; Vanazzi A; Negri M; Liptrott SJ; Bartosek AA; Miani M; Di Sanzo A; Cavalli F; Zucca E; Stathis A
    Hematol Oncol; 2021 Feb; 39(1):60-65. PubMed ID: 33103778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
    Nathwani BN; Anderson JR; Armitage JO; Cavalli F; Diebold J; Drachenberg MR; Harris NL; MacLennan KA; Müller-Hermelink HK; Ullrich FA; Weisenburger DD
    J Clin Oncol; 1999 Aug; 17(8):2486-92. PubMed ID: 10561313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
    Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
    Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Slawik HR; Bückner U; Otremba B; Sauer A; Zahn MO; Wetzel N; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2020 Aug; 38(3):344-352. PubMed ID: 32383192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
    Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
    Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Hsu A; Kurt H; Zayac AS; Olszewski AJ
    Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
    Cheah CY; Opat S; Trotman J; Marlton P
    Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
    Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
    Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
    Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
    Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
    Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.